1174997-03-5

Upstream product

• 23833-99-0 4-chloro-8-nitroquinoline 
• 123-30-8 4-amino-phenol 

Downstream Products

• 1174997-07-9 N-[4-(8-nitroquinolin-4-yloxy]phenyl]-4-chloro-3-trifluoromethylbenzamide 
• 1174997-05-7 1-[4-(8-nitroquinolin-4-yloxy)phenyl]-3-(4-chloro-3-trifluoromethylphenyl)urea 
• 1313019-82-7 C₂₃H₁₃F₄N₃O₄ 
• 1313019-78-1 C₂₂H₁₃BrF₃N₃O₅S 
• 1313019-80-5 C₂₄H₁₃F₆N₃O₄ 
• 1313019-76-9 C₂₂H₁₃F₃N₄O₇S 

Relevant academic research and scientific papers

Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf

STAT3 is a transcription factor that modulates survival-directed transcription. It is persistently activated in many human cancers. Literature has shown that sorafenib, Raf kinase inhibitor, reduces Phospho-STAT3 and induces cell death. A series of sorafenib derivatives were synthesized as new inhibitors for STAT3. Urea, sulfonamide, and carboxamide linkers brought out different SARs from the end of sorafenib. Urea and carboxamide linked derivatives showed greater inhibition against STAT3 activity than sulfonamide linked derivatives. In particular, 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4- (4-cyanophenoxy)phenyl)urea (1), a urea linker, was as potent as sorafenib in reducing P-STAT3 level and cell death but no inhibition for Raf activity. Such result provides a new lead for the design of STAT3 inhibitors.

AMINOQUINOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided are a novel aminoquinoline compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, preparation method thereof, and a pharmaceutical composition for preventing or treating cutaneous cancer, comprising the aminoquinoline co

Aminoquinoline derivatives with antiproliferative activity against melanoma cell line

The synthesis of a novel series of aminoquinoline derivatives 1a-p and their antiproliferative activities against A375 human melanoma cell line were described. Most compounds showed superior antiproliferative activities to Sorafenib as a reference compoun